James D. Watson Institute of Genome Sciences

Mount Sinai Announces New System Chief of Genomic Medicine

Retrieved on: 
Tuesday, September 26, 2023
Genomic Health, Cleveland Clinic, University, Population health, Genetics, Icahn School of Medicine at Mount Sinai, Public, Yale New Haven Health System, Murray, Brigham and Women's Hospital, University college, Research, Department of Medicine – University of Pamplona, DSM-IV codes, Mount Sinai, Genetic distance, Doctor of Philosophy, Harvard Medical School, Publication, MD, American College of Medical Genetics and Genomics, Patient, Division, Internal medicine, Cancer, James D. Watson Institute of Genome Sciences, Clinical, Diagnosis, Hospital, Medical genetics, American College, Health, Mount Sinai Health System, Penn State University College of Medicine, Vaccine, Pharmaceutical industry, Medical device, Genomics, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai. He will lead its efforts to harness the power of genomic discovery to develop new ways to prevent and treat diseases, including cancers, heart problems, and genetic disorders.

Key Points: 
  • Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
  • Before joining the Mount Sinai Health System, he led cutting-edge efforts to integrate genomic medicine into clinical care delivery at Harvard Medical School, Geisinger Community Medical Center, and Yale New Haven Health System.
  • "With the investment that the Mount Sinai Health System has made in genetics and genomics technology in the clinical and research arenas, we are making an impact upon the care we provide to patients in a significant way," said Monica Kraft, MD, the Murray M. Rosenberg Professor of Medicine and System Chair of the Department of Medicine at Mount Sinai Health System and Icahn Mount Sinai.

Mount Sinai Scientists Unlock Secrets of Red Blood Cell Transporter, Potentially Paving the Way for New Drugs

Retrieved on: 
Friday, September 8, 2023
Willard, Amgen, Sloan Research Fellowship, Drug development, University, Icahn School of Medicine at Mount Sinai, Cancer, Physiology, Mount Sinai, Doctor of Philosophy, National Institutes of Health, Disorder, Movement, Assistant, McKnight Foundation Collaborative Crop Research Program, Associate, Bangladesh Technical Education Board, Nature Structural & Molecular Biology, All but dissertation, Protein, MD, SLC, University of California, Berkeley, Blood, James D. Watson Institute of Genome Sciences, DOI, Genetic, Anemia, European Review for Medical and Pharmacological Sciences, Therapy, Pharmaceutical industry, Management, Neuroscience

NEW YORK, Sept. 8, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs. Details on the findings, which were reported in the September 7 issue of Nature Structural & Molecular Biology [DOI: 10.1038/s41594-023-01085-6], could lead to the development of more targeted medicines.

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
  • They discovered how these drugs block the transporter and devised novel compounds capable of achieving the same effect.
  • NEW YORK, Sept. 8, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
  • They discovered how these drugs block the transporter and devised novel compounds capable of achieving the same effect.

Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy

Retrieved on: 
Thursday, August 3, 2023
San Francisco, Doctor of Public Health, Mayo Clinic, University, University of Minnesota, Icahn School of Medicine at Mount Sinai, Neoplasm, University of Washington, Cohort (statistics), New York University Grossman School of Medicine, University of California, San Francisco, Baylor University, National Cancer Institute, Toxicity, MBA, Research, Mount Sinai, Doctor of Philosophy, University of Miami, Proteomics, MS, Amanda Paulovich, MD Anderson Cancer Center, University of Michigan School of Kinesiology, Death, Protein, Michigan Medicine, Patient, James D. Watson Institute of Genome Sciences, Baylor College of Medicine, University of Arkansas, Mortality, Trial of the century, Fred Hutchinson Cancer Research Center, Ovarian cancer, Dana–Farber Cancer Institute, Vaccine, Pharmaceutical industry, Medical imaging, Management, Genetics, MD, Cell, Medicine

NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

Key Points: 
  • The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • The multicenter study, published online August 3 in Cell [DOI#: 10.1016/j.cell.2023.07.004], reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • Currently, there's no way to distinguish refractory cases (who never respond to chemotherapy), leading some patients to unnecessarily experience the adverse effects of platinum-based chemotherapy without the benefits.
  • The investigators studied 242 tumors samples collected from HGSOC patients comprising both chemo-refractory and chemo-responsive individuals before they received chemotherapy.

PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
SAB, Informatics, Learning, Medical school, Olga Troyanskaya, University, Abraxis BioScience, James D. Watson Institute of Genome Sciences, United States Air Force Scientific Advisory Board, Human, Research, University of Richmond School of Law, University of Washington Information School, Structural biology, School, Biology, Simons Foundation, Computer science, Flatiron Institute, Integrated Genome Browser, Management, Genomics, Stanford University, Princeton University, Medicine

MENLO PARK, Calif., May 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Olga Troyanskaya, Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board (SAB) and Jay Shendure, Ph.D. as Chair. Dr. Shendure is a Professor of Genome Sciences at the University of Washington.

Key Points: 
  • "I am so honored to have Dr. Troyanskaya join PacBio's Scientific Advisory Board," said Christian Henry, President and Chief Executive Officer of PacBio.
  • Dr. Shendure has been a member of the Scientific Advisory Board since its inception and his contributions are critical to our success."
  • "I'm looking forward to working with PacBio and the other Scientific Advisory Board members and learning from them," said Dr. Troyanskaya.
  • "I want to thank Dr. Puglisi for his dedication to the Scientific Advisory Board," said Mark Van Oene, Chief Operating Officer at PacBio.

Behind the Scenes of a Major Genomic Discovery: Eimear Kenny plays an integral role in an international scientific effort that produces a more inclusive genome reference

Retrieved on: 
Wednesday, May 10, 2023
Gene conversion, DNA, Genomic Health, Human, Nature, Human genome, National Human Genome Research Institute, Icahn School of Medicine at Mount Sinai, Principal investigator, Mutation, Research, Medicine, Mount Sinai, Genomics, Doctor of Philosophy, Bangladesh Technical Education Board, NHGRI, Genetics, DOI, Chromosome, MD, Collection, James D. Watson Institute of Genome Sciences, Nature Biotechnology, Diagnosis, Health, Bias, Gene, Genome, Antibiotics, Medical device, Vaccine, Agriculture, Science

NEW YORK, May 10, 2023 /PRNewswire-PRWeb/ -- Eimear Kenny, PhD, had just completed undergrad and was working in her first computational genomics job more than 20 years ago when scientists announced the first (nearly) complete sequencing of the human genome—what was considered at the time to be the fundamental blueprint for all humans. The Human Genome Project aimed to map the entire genome in an effort to accelerate the diagnosis and eventual treatment of common and rare diseases.

Key Points: 
  • The Human Genome Project aimed to map the entire genome in an effort to accelerate the diagnosis and eventual treatment of common and rare diseases.
  • The work was led by the international Human Pangenome Reference Consortium, a group funded by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.
  • "We have had a single human reference for the past 20 years, and this genome reference has been extraordinarily powerful.
  • See press release issued by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health: https://www.genome.gov/news/news-release/scientists-release-a-new-human-...

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine With Epigenetic Engineering

Retrieved on: 
Tuesday, July 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Engineering, Manufacturing, Clinical Trials, Stanford University, AAV, GEMS, Gene expression, Gene, Biotechnology, Horizons Ventures, University of Maryland School of Medicine, Genetic engineering, Systems biology, University of Oxford, CRISPR interference, Coronavirus Scientific Advisory Board (Turkey), LinkedIn, Neuroscience, Genomics, University of California, Berkeley, CRISPR, Cas, Scientific Advisory Group for Emergencies, Bio, Patient, University of California, San Francisco, University of Washington Department of Bioengineering, Ludwig Cancer Research, Patent, Institute, Science Publishing Group, CRISPR/Cpf1, Human Genome Sciences, A1AD, Doctor of Philosophy, Department, Synthetic biology, Epigenome, Twitter, University, James D. Watson Institute of Genome Sciences, Industry, Maryland School, FSHD, Pharmaceutical industry, Vaccine, Management, Cas9, Biological engineering

Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.

Key Points: 
  • Epic was founded by Stanley Qi, Ph.D., a renowned bioengineer and named co-inventor on the CRISPR patent held by the University of California.
  • The company additionally launches with an exclusive license from Stanford University to the ultracompact DNA-binding protein CasMINI for human use.
  • The platform that Epic Bio has built is unparalleled in the field of epigenetic engineering.
  • Epic Bio was founded by Stanley Qi, Ph.D., whose fundamental work in epigenetic engineering includes the invention of CRISPRa (activation) and CRISPRi (interference).